Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMERICA INCBMRA · Entity 8171 | Director | December 10, 2020 | December 12, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMERICA INC
Report date December 10, 2020 · Filed December 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,736 |
Reported balance
After 2020-10-05 transaction · row 1
1 source rowRow 1 · 2020-10-05 · Gift · Disposed 20,000 · Balance 146,736 F1: Transaction was a gift, no monetary price assigned |
| Non-qualified stock optionSEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2030-12-10 | Direct | 175,000 |
Reported balance
After 2020-12-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-10 · Grant · Acquired 20,000 · Balance 175,000 F2: Not applicable |
| Common StockSEC Table I · non-derivative | IndirectSpouse | 5,900 |
Reported balance
Holding disclosure · report date 2020-12-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,900 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction was a gift, no monetary price assigned
F2: Not applicable
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DYNAVAX TECHNOLOGIES CORP
Report date February 10, 2026 · Filed February 10, 2026
Section 16 reporting ended · disclosed 2026-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock - Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 1
1 source rowRow 1 · 2026-02-10 · Disposition to issuer · Disposed 42,663 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-10 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-10 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.68 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.20 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.18 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-10 · Disposition to issuer · Disposed 28,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").
F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price.
F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,500 | Not disclosed Strike: $10.18 | Not disclosed |
DisclosureSEC source: 0001286710-26-000002 · form4-02102026_040203.xml · derivative · entry 7 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,500 | Not disclosed Strike: $11.85 | Not disclosed |
DisclosureSEC source: 0001286710-26-000002 · form4-02102026_040203.xml · derivative · entry 6 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,500 | Not disclosed Strike: $11.20 | Not disclosed |
DisclosureSEC source: 0001286710-26-000002 · form4-02102026_040203.xml · derivative · entry 5 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,500 | Not disclosed Strike: $11.68 | Not disclosed |
DisclosureSEC source: 0001286710-26-000002 · form4-02102026_040203.xml · derivative · entry 4 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $8.20 | Not disclosed |
DisclosureSEC source: 0001286710-26-000002 · form4-02102026_040203.xml · derivative · entry 3 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001286710-26-000002 · form4-02102026_040203.xml · derivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerCommon Stock - Restricted Stock Units | 42,663 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001286710-26-000002 · form4-02102026_040203.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 17:39 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Option (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $10.18 | $0.00 |
DisclosureSEC source: 0001029142-25-000091 · wk-form4_1749850783.xml · derivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Commont Stock · 28,500 shares Expires 2032-06-10 F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 17:39 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantCommon Stock | 5,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001029142-25-000091 · wk-form4_1749850783.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,663 F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 17:37 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | SaleCommon Stock | 3,615 | $11.93 | $43,126.95 |
DisclosureSEC source: 0000950170-24-068141 · ownership.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,905 Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:18 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000950170-24-065571 · ownership.xml · derivative · entry 5 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2024-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:18 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Tax withholdingCommon Stock | 3,885 | $11.39 | $44,250.15 |
DisclosureSEC source: 0000950170-24-065571 · ownership.xml · nonDerivative · entry 3 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,520 F2 · shares: Represents the number of shares withheld to cover option exercise cost. Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:18 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 7,500 | $5.90 | $44,250.00 |
DisclosureSEC source: 0000950170-24-065571 · ownership.xml · nonDerivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:18 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $11.79 | $0.00 |
DisclosureSEC source: 0000950170-24-065571 · ownership.xml · derivative · entry 4 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-22 F3 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:18 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantCommon Stock | 5,357 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-065571 · ownership.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,905 F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:20 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Options (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $11.20 | $0.00 |
DisclosureSEC source: 0001209191-23-033154 · doc4.xml · derivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-05-25 F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:20 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantCommon Stock | 5,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033154 · doc4.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,548 F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. The reporting person has reported prior awards of restricted stock units in Table II on Form 4. The total reported in Column 5 includes 5,357 newly awarded restricted stock units, 5,357 restricted stock units previously reported in Table II, and 20,834 shares of common stock. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:21 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $4.97 | Not disclosed |
DisclosureSEC source: 0001209191-22-045321 · doc4.xml · derivative · entry 3 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: These options fully-vested on May 30, 2020, upon the one-year anniversary of the grant date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:21 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | SaleCommon Stock | 15,000 | $17.17 | $257,550.00 |
DisclosureSEC source: 0001209191-22-045321 · doc4.xml · nonDerivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,834 F1 · price: This transaction was executed in multiple trades at prices ranging from $17.16 to $17.20; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:21 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 15,000 | $4.97 | $74,550.00 |
DisclosureSEC source: 0001209191-22-045321 · doc4.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 27, 2022 17:01 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 22,500 | Not disclosed Strike: $11.68 | Not disclosed |
DisclosureSEC source: 0001209191-22-032611 · doc4.xml · derivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-05-25 F3 · price: Not applicable. F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 17:01 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantRestricted Stock Unit · Derivative | 5,357 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032611 · doc4.xml · derivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,357 Underlying: Common Stock · 5,357 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 19:32 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionWarrant (Right to Buy) · Derivative | 4,167 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001209191-21-053376 · doc4.xml · derivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,167 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable F1 · derivative.exercise_date: Warrants were issued in connection with a financing transaction dated August 12, 2019 and were immediately exercisable upon issuance and have an expiration date of February 12, 2022. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 19:32 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 4,167 | $4.50 | $18,751.50 |
DisclosureSEC source: 0001209191-21-053376 · doc4.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 19:03 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $8.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-037418 · doc4.xml · derivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-05-27 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 28, 2022, on the one year anniversary of the grant date. Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 01:26 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 20,000 | Not disclosed Strike: $6.36 | Not disclosed |
DisclosureSEC source: 0001513162-20-000240 · primary_doc.xml · derivative · entry 3 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-10 F2 · price: Not applicable Read SEC document |
| October 05, 2020 Filed Dec 12, 2020 01:26 UTC | BIOMERICA INC BMRA · Entity 8171 | GiftCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001513162-20-000240 · primary_doc.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,736 F1 · price: Transaction was a gift, no monetary price assigned Read SEC document |
| May 28, 2020 Filed May 29, 2020 16:32 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001209191-20-032949 · doc4.xml · derivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-27 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 28, 2021, on the one year anniversary of the grant date. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:29 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon Qualified Stock Option · Derivative | 30,000 | Not disclosed Strike: $2.81 | Not disclosed |
DisclosureSEC source: 0001513162-19-000258 · primary_doc.xml · derivative · entry 3 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 30,000 shares Expires 2029-12-20 F1 · price: Not applicable. Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 19:24 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | PurchaseWarrant (Right to Buy) · Derivative | 4,167 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001209191-19-045638 · doc4.xml · derivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 4,167 shares Expires 2022-02-12 F1 · derivative.exercise_date: Immediate Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 19:24 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | PurchaseCommon Stock | 16,667 | $3.00 | $50,001.00 |
DisclosureSEC source: 0001209191-19-045638 · doc4.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Read SEC document |
| May 30, 2019 Filed May 31, 2019 18:27 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $4.97 | Not disclosed |
DisclosureSEC source: 0001209191-19-033720 · doc4.xml · derivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-05-29 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 30, 2020, on the one year anniversary of the grant date. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:01 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon Qualified Stock Option · Derivative | 35,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001513162-18-000322 · primary_doc.xml · derivative · entry 3 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 35,000 shares Expires 2028-12-20 F1 · price: Not applicable Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 19:23 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | SaleCommon Stock | 2,000 | $10.47 | $20,942.00 |
DisclosureSEC source: 0001209191-18-061656 · doc4.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The shares were sold at prices ranging from $10.47 to $10.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 26, 2018 Filed Oct 26, 2018 18:25 UTC | BIOMERICA INC BMRA · Entity 8171 | OtherNon Qualified Stock Option · Derivative | 25,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001513162-18-000271 · primary_doc.xml · derivative · entry 3 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 25,000 shares Expires 2018-10-30 F1 · shares: To report exercise of stock option. F2 · price: Consists of various options reported previously with varying dates and prices both expiring and excercisable. Read SEC document |
| October 26, 2018 Filed Oct 26, 2018 18:25 UTC | BIOMERICA INC BMRA · Entity 8171 | Exercise / conversionCommon Stock | 25,000 | $0.75 | $18,750.00 |
DisclosureSEC source: 0001513162-18-000271 · primary_doc.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: To report exercise of stock option. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 17:02 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $15.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-034758 · doc4.xml · derivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-05-30 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 31, 2019, on the one year anniversary of the grant date. Read SEC document |
| May 23, 2018 Filed May 25, 2018 17:45 UTC | BIOMERICA INC BMRA · Entity 8171 | OtherCommon Stock | 8,000 | $3.73 | $29,840.00 |
DisclosureSEC source: 0001513162-18-000140 · primary_doc.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,736 F1 · kind: Purchased through an S-3 registration statement filed 06/30/2017, file #333-219130. (Prospectus filed 12/04/2017) Read SEC document |
| January 25, 2018 Filed Jan 25, 2018 22:05 UTC | BIOMERICA INC BMRA · Entity 8171 | PurchaseCommon Stock | 2,500 | $4.18 | $10,450.00 |
DisclosureSEC source: 0001513162-18-000033 · primary_doc.xml · nonDerivative · entry 4 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 5,900 Read SEC document |
| January 25, 2018 Filed Jan 25, 2018 22:05 UTC | BIOMERICA INC BMRA · Entity 8171 | PurchaseCommon Stock | 5,700 | $4.18 | $23,826.00 |
DisclosureSEC source: 0001513162-18-000033 · primary_doc.xml · nonDerivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,736 Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 22:05 UTC | BIOMERICA INC BMRA · Entity 8171 | PurchaseCommon Stock | 3,400 | $4.18 | $14,212.00 |
DisclosureSEC source: 0001513162-18-000033 · primary_doc.xml · nonDerivative · entry 3 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 3,400 Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 22:05 UTC | BIOMERICA INC BMRA · Entity 8171 | PurchaseCommon Stock | 200 | $4.18 | $836.00 |
DisclosureSEC source: 0001513162-18-000033 · primary_doc.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,036 Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 23:48 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon qualified stock option · Derivative | 25,000 | Not disclosed Strike: $3.90 | Not disclosed |
DisclosureSEC source: 0001513162-18-000028 · primary_doc.xml · derivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-22 F2 · price: Not applicable. F1 · derivative.exercise_date: Exercisable 01/22/2019. Read SEC document |
| June 02, 2017 Filed Jun 2, 2017 18:05 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $5.90 | Not disclosed |
DisclosureSEC source: 0001209191-17-037412 · doc4.xml · derivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2024-06-01 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on June 2, 2018, on the one year anniversary of the grant date. Read SEC document |
| November 17, 2016 Filed Nov 18, 2016 18:02 UTC | BIOMERICA INC BMRA · Entity 8171 | OtherNon-qualified stock option · Derivative | 25,000 | Not disclosed Strike: $0.43 | Not disclosed |
DisclosureSEC source: 0001513162-16-001083 · primary_doc.xml · derivative · entry 2 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 25,000 shares Expires 2017-01-05 F1 · price: Consists of various options previously reported with varying dates expiring and prices exercisable Read SEC document |
| November 17, 2016 Filed Nov 18, 2016 18:02 UTC | BIOMERICA INC BMRA · Entity 8171 | Exercise / conversionCommon Stock | 25,000 | $0.43 | $10,750.00 |
DisclosureSEC source: 0001513162-16-001083 · primary_doc.xml · nonDerivative · entry 1 CANO FRANCIS · CIK 0001286710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.